HealthStream, Inc. HSTM R2K
Company Overview
HealthStream, Inc. provides Software-as-a-Service (SaaS) based applications for healthcare organizations in the United States. The company offers hStream, a technology platform; CredentialStream, provides healthcare organizations with tools to support the provider lifecycle management from recruiting, application submission, verification of licensure and other credentials, privileging, appointments by credentialing committees, enrollment, network, management, onboarding, and performance evaluations of providers; ShiftWizard; and Competency Suite, AI/ML-driven clinical competency development system. It also provides applications for performance appraisal, competency management, disclosure management, clinical competency, assessment, development, simulation-based education, clinical rotation and onboarding management, quality management, and industry training. The company's solutions help healthcare organizations in meeting their ongoing learning, clinical development, credentialing, and scheduling needs. It serves the healthcare industry, including private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies, and nursing schools and students. The company was incorporated in 1990 and is headquartered in Nashville, Tennessee.
Why Investors Should Care
Revenue has grown at a 11.0% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $304.06M (+4.3% YoY); net profit $18.34M.
- Trailing 12 Months Year-on-year growth — revenue +10.5%, earnings +42.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.0%, profit CAGR 1.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.98% |
| 1 Year: | 10.50% |
Compounded Profit Growth
| 5 Years: | 1.72% |
| 1 Year: | 42.90% |
Stock Price Performance
| 1 Year: | +5.45% |
| 6 Months: | +29.00% |
| 3 Months: | +39.73% |
| 1 Month: | +8.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.98 · Neutral
P/E of 42.42 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HSTM HealthStream, Inc. R2K | 28.42 | 42.42 | $830.30M | 0.51% | 5.11% | 5.57% | 10.98% | 1.72% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.92M | 54.74M | 54.86M | 57.01M | 59.92M | 65.19M | 63.78M | 62.45M | 61.57M | 60.55M | 60.88M | 63.47M | 64.82M | 64.09M | 65.37M | 65.64M | 67.28M | 68.95M | 69.20M | 70.34M | 72.76M | 71.56M | 73.09M | 73.48M | 74.40M | 76.47M | 81.20M |
| Operating Income | 3.17M | 4.11M | 3.88M | 3.30M | 4.11M | 4.74M | 4.79M | 2.56M | 4.33M | 2.49M | 2.32M | 1.29M | 2.37M | 2.80M | 2.73M | 3.73M | 4.26M | 4.66M | 5.37M | 2.27M | 3.75M | 7.24M | 4.30M | 3.13M | 3.30M | 3.43M | 1.78M | 4.04M | 2.95M | 2.38M | 2.89M | 4.01M | 4.86M | 5.69M | 4.41M | 6.50M | 4.38M | 5.89M | 7.57M | 7.51M |
| Net Income | 1.94M | 2.42M | 2.30M | 1.95M | 2.36M | 3.44M | 2.72M | 1.47M | 2.61M | 1.50M | 1.40M | 1.16M | 1.28M | 2.27M | 2.50M | 23.85M | 2.54M | 3.04M | 5.97M | 2.40M | 3.71M | 7.09M | 3.44M | 2.63M | 2.29M | 2.44M | 1.50M | 2.89M | 3.08M | 3.67M | 2.62M | 4.13M | 3.87M | 5.23M | 4.17M | 5.72M | 4.33M | 5.39M | 6.09M | 5.91M |
| Diluted EPS | 0.07 | 0.09 | 0.08 | 0.07 | 0.08 | 0.12 | 0.10 | 0.05 | 0.08 | 0.05 | 0.04 | 0.04 | 0.04 | 0.07 | 0.08 | 0.74 | 0.08 | 0.09 | 0.18 | 0.07 | 0.11 | 0.22 | 0.11 | 0.08 | 0.07 | 0.08 | 0.05 | 0.09 | 0.10 | 0.12 | 0.09 | 0.13 | 0.13 | 0.17 | 0.14 | 0.19 | 0.14 | 0.18 | 0.20 | 0.20 |
| R&D Expense | 2.61M | 2.78M | 3.21M | 3.55M | 4.29M | 4.21M | 4.65M | 5.82M | 6.20M | 7.02M | 7.24M | 7.26M | 5.78M | 6.15M | 6.00M | 6.00M | 6.55M | 6.60M | 6.93M | 7.64M | 7.20M | 7.47M | 7.83M | 8.19M | 9.53M | 10.34M | 10.34M | 10.41M | 10.58M | 11.48M | 11.68M | 11.03M | 10.90M | 12.03M | 12.08M | 12.10M | 12.05M | 12.07M | 12.11M | 13.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.40M | 65.75M | 82.07M | 103.73M | 132.27M | 170.69M | 209.00M | 192.12M | 214.90M | 231.62M | 254.11M | 244.83M | 256.71M | 266.83M | 279.06M | 291.65M | 304.06M |
| Operating Income | 5.12M | 7.06M | 11.34M | 13.46M | 14.67M | 16.38M | 13.56M | 7.17M | 9.41M | 15.49M | 14.72M | 15.82M | 8.05M | 12.45M | 16.02M | 21.29M | 20.24M |
| Net Income | 13.97M | 4.15M | 6.94M | 7.64M | 8.42M | 10.39M | 8.62M | 3.75M | 10.00M | 32.22M | 15.77M | 14.09M | 5.84M | 12.09M | 15.21M | 20.01M | 18.34M |
| Diluted EPS | 0.64 | 0.18 | 0.29 | 0.28 | 0.30 | 0.37 | 0.28 | 0.12 | 0.31 | 1.00 | 0.49 | 0.44 | 0.18 | 0.39 | 0.50 | 0.66 | 0.61 |
| R&D Expense | 6.29M | 6.99M | 7.47M | 8.61M | 11.76M | 16.46M | 24.21M | 24.23M | 24.15M | 25.73M | 29.11M | 32.30M | 41.66M | 44.28M | 45.54M | 48.89M | 50.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 82.01M | 154.24M | 174.53M | 212.59M | 257.26M | 379.57M | 396.00M | 411.12M | 441.95M | 489.54M | 500.31M | 486.75M | 497.74M | 499.94M | 510.77M | 520.37M |
| Total Equity | 36.76M | 51.82M | 56.79M | 120.92M | 132.20M | 149.43M | 167.86M | 280.32M | 286.11M | 300.17M | 318.95M | 338.17M | 334.06M | 339.02M | 334.06M | 340.75M | 359.36M | 354.02M |
| Cash & Equivalents | 4.11M | 12.29M | 17.87M | 76.90M | 41.37M | 59.54M | 82.00M | 82.01M | 49.63M | 84.77M | 134.32M | 131.54M | 36.57M | 46.91M | 46.02M | 40.33M | 59.47M | 36.16M |
| Current Liabilities | - | - | 24.75M | 32.45M | 35.03M | 56.21M | 77.26M | 89.08M | 94.97M | 101.07M | 106.85M | 105.19M | 119.44M | 100.35M | 117.21M | 118.36M | 115.69M | 124.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 11.57M | 16.12M | 19.75M | 22.53M | 26.28M | - | - | 24.23M | 46.71M | 43.25M | 65.66M | 35.87M | 42.38M | 51.19M | 63.97M | 57.66M | 63.32M |
| Investing Cash Flow | -3.07M | -10.38M | -17.11M | -59.00M | -14.99M | - | - | -56.66M | -11.58M | 36.56M | -67.52M | -110.41M | -25.72M | -28.39M | -56.60M | -33.97M | -50.35M |
| Financing Cash Flow | -319.00K | -159.00K | 56.39M | 934.00K | 6.88M | - | - | 46.00K | 1.00K | -30.25M | -916.00K | -20.49M | -6.21M | -23.70M | -13.04M | -4.52M | -36.27M |
| Capital Expenditure | -1.79M | -2.62M | -4.12M | -4.32M | -4.44M | -4.54M | -8.09M | -4.81M | -5.51M | -7.17M | -22.00M | -1.99M | -3.42M | -1.77M | -2.20M | -1.40M | -3.69M |
| Free Cash Flow | 9.78M | 13.49M | 15.64M | 18.21M | 21.84M | - | - | 19.43M | 41.20M | 36.08M | 43.66M | 33.89M | 38.97M | 49.42M | 61.77M | 56.26M | 59.63M |
| Share Buybacks | - | 379.00K | - | - | - | - | - | - | - | - | 0 | 20.02M | 5.01M | 23.14M | 8.93M | 0 | 30.02M |
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.10M | 3.40M | 3.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 8.9% | 10.7% | 13.8% | 13.0% | 11.1% | 9.6% | 6.5% | 3.7% | 4.4% | 6.7% | 5.8% | 6.5% | 3.1% | 4.7% | 5.7% | 7.3% | 6.7% |
| Net Margin % | 24.3% | 6.3% | 8.5% | 7.4% | 6.4% | 6.1% | 4.1% | 2.0% | 4.7% | 13.9% | 6.2% | 5.8% | 2.3% | 4.5% | 5.5% | 6.9% | 6.0% |
| ROE % | 27.0% | 7.3% | 5.7% | 5.8% | 5.6% | 6.2% | 3.1% | 1.3% | 3.3% | 10.1% | 4.7% | 4.2% | 1.7% | 3.6% | 4.5% | 5.6% | 5.2% |
| ROCE % | - | 12.3% | 9.3% | 9.6% | 9.4% | 9.1% | 4.7% | 2.4% | 3.0% | 4.6% | 3.8% | 4.2% | 2.1% | 3.3% | 4.2% | 5.4% | 5.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.18% | 3.85M | $110.82M |
| 2 | Dimensional Fund Advisors LP | 4.98% | 1.46M | $41.89M |
| 3 | Copeland Capital Management, LLC | 4.37% | 1.28M | $36.73M |
| 4 | Vanguard Capital Management LLC | 3.59% | 1.05M | $30.15M |
| 5 | State Street Corporation | 3.41% | 995.56K | $28.64M |
| 6 | Vanguard Portfolio Management LLC | 3.16% | 921.85K | $26.52M |
| 7 | Two Sigma Investments, LP | 2.89% | 844.42K | $24.29M |
| 8 | Geode Capital Management, LLC | 2.45% | 714.75K | $20.56M |
| 9 | Renaissance Technologies, LLC | 1.64% | 477.85K | $13.75M |
| 10 | JPMORGAN CHASE & CO | 1.55% | 453.74K | $13.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HSTM
[SCHEDULE 13G] HEALTHSTREAM INC Passive Investment Disclosure (>5%) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVzBUVXR0QXA0STFfUHRva2hSS0ppX1JNWlJOa3NFRWpOMVllMnBYY3lzRUdzc0l2U3VfN1VIWHN0NFFJQ0pvNk5ONTdMNTZ3R1NuZndiQmpRREh2UDFZdFhSbzdNVG9vZGdkWFJHSUFlb2hIWXNnNFpCRjRvTGNsdHlSTFVtRWRidW1iNm…
HSTM or SIFY: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNR0M1U1hYS0x6dURoSVZTbk1fN3VQRkhtbzZqVXZMTFhiNlJhOXktU19UWi1ZazNkdlczNkE2RmhjUUFFU1p6SE1jY0F6QlZEVUg1Y0toTEUtY0RBUC1uSDZwLWswMC1aNmNDWTdDSlNKQ0tFejVzTkluazFTMWY3aG9CY21LQUlDYVhOM0…
Healthstream director Linda Rebrovick sells $174,000 in HSTM stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQMGwzc0kxN0pvaGVnb3JGR2p5cEtqMGt5Q3ZuS2NQTmNvNXpiM3k1eEo4N2czckRzLTM4UC1GWkpPWFhab3MwbDdmSGFJT1M1QUdscm8xdFp3VjhIUEZXS0JtVFYwd0U1ZGQ1U3R4dGdqUFIxMl9XLXNFbl9GcUVHQWN4X3IwdDJYbHBPYk…
HealthStream, Inc. (HSTM) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNdE1tMkR1UHdUdHRLb0syQm1NZ09kSGxfZzhoTHc1OURLdkJlQ3h6ajdiUFRwNl84RWp1UGMwM0ZMQ3o2c3BpTmRGRkVHaEFSLVgxVHgtSE94SEpyWHRoSzlWZUtGcVh1NjZQdFlJeHJ6Smo3QUhjNlFNMjZ1dkFBVEtONG1hakZ3bDQybW…
Precision Trading with Healthstream Inc. (HSTM) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQeXdDRm51ejFJTllqekNRUW1uOS1aTTRtZHhZYXJJQUM0dXFJa01FOWpERENmb0ZMdk5Bck1WVnJ6amtNeHhoSS1hejREQlJzWFJNSjVxQzN0Nktydm1oX21pampJZ1BZdDFEWWFSZlF6RmlHbEhpVF9YU2dBT25lRTJtaEhzd0w3NDlKbT…
Enterprise value to revenue forward of HealthStream, Inc. – NASDAQ:HSTM - TradingView
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOdWNXR0VoVlR2bG9tNUxjVHNQaUt3eGswM1YwTXNBeXdJb3BBczVjdDRmV3AxUjNFcGpGOWlLSWRVR01zNUQzTW9veXdicWV0Q3BqNE02Y21kUkc4Qk85ZXFtWF9taHhWRC1tOWE1cW5jR2ZlbFFiX2NXN0RYSnVBR2FnOGRlckw1TzNKYn…
HSTM — Frequently Asked Questions
What is the current share price of HealthStream, Inc. (HSTM)?
As of 2026-07-14 21:23 PDT, HealthStream, Inc. (HSTM) trades at $28.42 on NasdaqGS. Its 52-week range is $19.82 to $29.17.
What is the market capitalisation of HSTM?
HealthStream, Inc. (HSTM) has a market capitalisation of $830.30M on NasdaqGS.
What is the P/E ratio of HSTM?
HSTM trades at a trailing price-to-earnings (P/E) ratio of 42.42. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.18.
Does HSTM pay a dividend?
HealthStream, Inc. (HSTM) currently offers a dividend yield of 0.51%.
What is the return on equity (ROE) of HSTM?
HSTM has a return on equity (ROE) of 5.57%. Its return on capital employed (ROCE) is 5.11%.
Is HSTM a good stock to buy?
This page provides a data-driven analysis of HealthStream, Inc. (HSTM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.